BOSTON--(BUSINESS WIRE)--Amwell® (NYSE: AMWL), a national telehealth leader, today announced the pricing of a public offering of 11,280,647 shares of its Class A common stock by certain stockholders (the “Selling Stockholders”) at a public offering price of $27.50 per share. In addition, the underwriters have been granted a 30-day option to purchase up to 1,692,097 additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions, from the Selling Stockholders. Amwell will not receive any proceeds from this offering.

The offering is expected to close on January 20, 2021, subject to customary closing conditions.

Morgan Stanley, Goldman Sachs & Co. LLC, Piper Sandler and UBS Investment Bank are acting as lead joint book-running managers for the offering. Credit Suisse, Cowen and Berenberg are acting as bookrunners for the proposed offering.

About Amwell

Amwell is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 2,000 hospitals and 55 health plan partners with over 36,000 employers, covering over 80 million lives.